A Phase 3 interventional study of YZJ-1139 and Zolpidem in Insomnia Disorder, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 16 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.
Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 115th largest by enrollment of the 162 interventional ones that give a count, is one of 18 that started in 2025, is one of 7 in phase 3, and was the 153rd registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:
Sichuan Academy of Medical Sciences · Sites in China
Ages 18–80
China Medical University, China · Sites in China
Ages 60+
Renmin Hospital of Wuhan University · Sites in China
Ages 18–79
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Huazhong University of Science and Technology · Sites in China
Ages 40–65 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 9 · Phase 4 13
First in 2006; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 88 across the 162 interventional studies, 200 across the 36 observational. Of the 82 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 198 have an industry lead sponsor. The 10 most frequent:
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. has 9 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
29 of the studies in Sleep Initiation and Maintenance Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07738809Capital University of Physical Education and Sports, ChinaEffects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms | 2026-11 |
| NCT07730762Xijing HospitalA Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During Pregnancy | 2026-11-30 |
| NCT07340268Zan WangThe Effects of Transcranial Current Stimulation on Insomnia | 2026-11-30 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 29 to your calendar (.ics) → With an account.
Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PSG results for 2 consecutive nights during the run-in period should meet the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: YZJ-1139
Drug: Zolpidem
Change from baseline of Mean Objective Wake After Sleep Onset (WASO)
WASO is defined as minutes of wake from the onset of persistent sleep until lights on as measured by polysomnography (PSG).
Time frame: Baseline, Day 1/Day 2, Day 27/Day 28
Change from baseline of Mean Objective Sleep Efficiency (SE)
SE is defined as percentage of time spent in bed asleep, calculated as total sleep time (TST) divided by interval from lights off until lights on as measured by PSG, multiplied by 100.
Time frame: Baseline, Day 1/Day 2, Day 27/Day 28
Change from baseline of Mean Objective Total Sleep Time (TST)
TST is defined as total sleep time measured by PSG.
Time frame: Baseline, Day 1/Day 2, Day 27/Day 28
Change from baseline of Mean Objective Latency to Persistent Sleep (LPS)
LPS is defined as latency to persistent sleep measured by PSG.
Time frame: Baseline, Day 1/Day 2, Day 27/Day 28
Change from baseline of Mean Subject Wake After Sleep Onset (sWASO)
sWASO is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.
Time frame: Baseline, Week1, Week 4
Change from baseline of Mean Subject Sleep Efficiency (sSE)
sSE is defined as percentage of time spent in bed asleep, calculated as subject total sleep time (sTST) divided by interval from lights off until lights on, multiplied by 100.
Time frame: Baseline, Week1, Week 4
Change from baseline of Mean subject Total Sleep Time (sTST)
sTST is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.
Time frame: Baseline, Week1, Week 4
Change from baseline of Mean Subjective Time to Sleep Onset (sTSO)
sTSO is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.
Time frame: Baseline, Week1, Week 4
Change from baseline of Mean Subjective Number of awakenings (sNAW)
sNAW is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.
Time frame: Baseline, Week1, Week 4
Change from baseline of Sleep structure (wakefulness, N1, N2, N3, rapid eye movement sleep [REM], non-rapid eye movement sleep [NREM])
Wakefulness, N1, N2, N3, REM, NREM are measured by PSG in minutes, and expressed as the percent change from time spent in bed (TIB) and TST.
Time frame: Baseline, Day 1/Day 2, Day 27/Day 28
Change from baseline of Sleep structure (REM latency, number of awakenings [NAW], arousal index for REM and NREM)
REM latency, NAW and the arousal index for REM and NREM are measured by PSG.
Time frame: Baseline, Day 1/Day 2, Day 27/Day 28
Change from baseline in the mean subjective sleep quality score
Subjective sleep quality score is a self-report assessment of participant perception of the effects of a medication on their sleep. Higher score indicated severe insomnia problem.
Time frame: Baseline, Week1, Week 4
Change from baseline in the ISI score
Insomnia Severity Index is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Higher score indicated severe insomnia problem.
Time frame: Baseline, Day15 and Day 28
Percentage of participants on each scale of Global Impression of Insomnia (PGI-I) each item
the PGI-I was a self-report assessment of participant perception of the effects of a medication on their sleep. The PGI-I had 3 items related to study medication effects (a) helped/worsened sleep, (b) decreased/increased time to fall asleep, (c) increased/decreased total sleep time, and 1 item related to perceived appropriateness of study medication strength. The first 3 items were answered on a 3-point scale (1=positive medication effect, 2=neutral medication effect, 3=negative medication effect) and the last item on a different 3 point scale (medication: 1=too strong, 2=just right, 3=too weak).
Time frame: Day15 and Day 28
Ran from Mar 2025 to primary completion in Jul 2025, 3 months.
Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 3 months is below that.
Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fazamorexant
Sleep Initiation and Maintenance Disorders →
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.